Search

for
Search:

Research

5 / 1000+ results

research A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system

6 citations , January 2024 in “International Journal of Dermatology”

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

research Shedding light on the FDA’s 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia

6 citations , September 2018 in “Journal of Dermatological Treatment”

This review examines the FDA's 510(k) approval process for low-level laser therapy devices used in treating androgenetic alopecia and reports no new clinical findings.

research FDA Reports of Alopecia as an Adverse Event to Isotretinoin

5 citations , July 2019 in “Journal of Cutaneous Medicine and Surgery”

Isotretinoin may cause hair loss, especially in women and young adults.

research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss

4 citations , July 2023 in “Nature Medicine”

The FDA approved a new Pfizer drug for hair loss in teens.

research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata

3 citations , November 2024 in “Clinical Research”

This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.

View more "fd" in research →

Community Join

5 / 951 results

community FDA Policy Shift Explained: What It Actually Means for PP405, VDPHL-01, Breezula and Hair Loss Drug Timelines

in Research/Science 42 upvotes 6 months ago

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

community US FDA will now default to only one clinical trial for drug applications, will this accelerate the release of PP405 and other drugs in clinical trials?

13 upvotes 6 months ago

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

community New warning by FDA on topical finasteride

in Research/Science 194 upvotes 1 year ago

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

community Finasteride alternative close to fda approval in the US

60 upvotes 3 months ago

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

community No more hair transplants - a new FDA-cleared fractional laser treatment called FoLix

105 upvotes 11 months ago

A new FDA-cleared fractional laser treatment called FoLix is discussed as a potential alternative to hair transplants, but users express skepticism due to its high cost, pain, and lack of proven results. Some users prefer traditional methods like Minoxidil, finasteride, steroid shots, and microneedling for hair growth.

View more "fd" in community →

Experts

2 / 5 results

Learn

— no results

Try a deeper search in learn →

Clinics